Skip to content

Application of OLIF (oblique lateral interbody fusion) in lumbar spinal tuberculosis

Application of OLIF (oblique lateral interbody fusion) in lumbar spinal tuberculosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400079815
Enrollment
Unknown
Registered
2024-01-12
Start date
2024-01-05
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal tuberculosis

Interventions

Anterior approach for lumbar tuberculosis:none
Posterior approach for lumbar tuberculosis:none
OLIF approach for lumbar tuberculosis:none

Sponsors

The First People’s Hospital of Hefei City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) From 18 to 70 years of age; (2) Diagnosis of lumbar tuberculosis was confirmed by clinical and radiographic examinations; (3) Antituberculosis drugs were administered for at least 4 weeks.

Exclusion criteria

Exclusion criteria: (1) Tuberculosis involvement of multiple lumbar spine levels; (2) Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) did not stabilize or decrease after 4 weeks of antituberculosis drugs; (3) Could not receive follow-up for at least one year; (4) A history of nervous system or mental illness; (5) Patients with active pulmonary tuberculosis, spinal tumors, or acute vertebral fractures of the thoracic and lumbar spine.

Design outcomes

Primary

MeasureTime frame
Oswestry disability index;visual analogue scale;C-reaction protein;erythrocyte sedimentation Rate;Cobb angle; blood loss;Operation time;

Countries

China

Contacts

Public ContactKe Zheng

Spinal Department of Orthopedics, The First People’s Hospital of Hefei City, Hefei

spinek2020@163.com+86 189 1967 9705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026